Streptomyces spp. culture filtrates reduced T4 infectivity to E. coli

A Streptomyces spp. culture was isolated and identified. Its filtrate was found to be able to destroy ORSV and CYmMV virus coat protein, and could be used to reduce the transmission of plant virus disease in vivo, in our previous study. We also tested and found that it can destroy the coat proteins of 13 other of plant viruses, suggesting that the mechanism of action is not specific to a few plant viruses. Aim: To test if this culture filtrate can destroy or affect the infectivity of non-plant viruses. Materials and methods: Streptomyces spp. were cultured in soybean-based culture medium for 14 days, and the culture was collected and filtered. T4 phage infection of E. coli was used as a model. E. coli was cultured on 0.75% TSA agar plates. The T4 phage was incubated with various concentrations of Streptomyces spp culture filtrate for 30 minutes, before adding to the E. coli lawn. Culture filtrates of two strains, the C5-6 and the SML-1, were used. T4 phage incubated with 300 ppm virusbom (a known anti-viral agent) was used as a positive control. The formation of T4 lysis colony was calculated for the plaque-forming unit (PFU). Results: The dilution of 1 in 8 of the culture filtrates reduced the number of phage colony on E. coli lawn. The infectivity was significantly reduced when T4 was incubated with the culture filtrate at 1/8 dilution when compared to the non-treated groups. The virusbom treated PFU was significantly reduced, in comparison with C5-6 treated group (P=0.013), and with SML-1 treated group (P=0.028) as per ANOVA test followed by Tukey post-hoc comparison. Summary: These data demonstrated that culture filtrates of Streptomyces spp. reduced T4 to E. coli infectivity and suggested that the anti-viral compounds in the filtrate is not specific to plant viruses. The application of the culture filtrate and its content might have broader applications.

[1]  S. Ekins,et al.  New targets for HIV drug discovery. , 2019, Drug discovery today.

[2]  R. Razonable.  Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus , 2011, Mayo Clinic Proceedings.

[3]  T. Dean,et al.  Enumeration of bacteriophage particles , 2011, Bacteriophage.

[4]  C. Chiu,et al.  Disinfection of Odontoglossum ringspot virus and Cymbidium mosaic virus from tools used during orchid cultivation. , 2010 .

[5]  J. McIntosh,et al.  Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists. , 2008, Journal of the American Pharmacists Association : JAPhA.

[6]  Hideo Tanaka,et al.  Production of poly(l-lactide)-degrading enzyme by Amycolatopsis orientalis for biological recycling of poly(l-lactide) , 2006, Applied Microbiology and Biotechnology.

[7]  Y. Nonomura,et al.  Alkaline serine protease produced by Streptomyces sp. degrades PrP(Sc). , 2004, Biochemical and biophysical research communications.

[8]  G. Arreaza,et al.  Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease. , 2003, Bioorganic & medicinal chemistry letters.

[9]  A. Paul,et al.  Degradation of poly(3-hydroxybutyrate) by soil streptomycetes , 1999 .

[10]  D. Michaud.  Gel electrophoresis of proteolytic enzymes , 1998 .

[11]  A. Patick,et al.  Protease Inhibitors as Antiviral Agents , 1998, Clinical Microbiology Reviews.

[12]  C. Barbas,et al.  Selection and evolution of high-affinity human anti-viral antibodies. , 1996, Trends in biotechnology.

[13]  E. Wimmer,et al.  Viral proteases as targets for chemotherapeutic intervention , 1992, Current Opinion in Biotechnology.

[14]  E. Hiebert,et al.  Purification, characterization and immunological analysis of nuclear inclusions induced by bean yellow mosaic and clover yellow vein potyviruses. , 1988 .